Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Optimi Health investor Cathay acquires 102,500 shares

By The Northwire Desk — AI Analysis Jan 21, 2026 · 21:01 OPTI · 0.34 Optimi Health Corp
OPTI · Price

Executive Summary

  • Cathay Visions Enterprises Ltd. acquired 102,500 common shares of Optimi Health Corp. in the public market, triggering an Early Warning Report under National Instrument 62-103.
  • Following the acquisition, Cathay Visions Enterprises Ltd.'s total ownership increased to approximately 13.13% of the issued and outstanding common shares on an undiluted basis.
  • The acquiror retains the right to acquire additional securities or dispose of existing holdings in the future based on market conditions and investment opportunities.

Key Details

  • Acquirer: Cathay Visions Enterprises Ltd.
  • Target Issuer: Optimi Health Corp.
  • Transaction Type: Acquisition of common shares in the public market.
  • Shares Acquired: 102,500 common shares.
  • Purchase Price: 32 cents per share.
  • Pre-Transaction Ownership: 12,583,938 common shares (approximately 13.02% of issued and outstanding shares on an undiluted basis).
  • Post-Transaction Ownership:
    • Common Shares: 12,686,438 shares.
    • Warrants: 533,333 warrants.
    • Stock Options: 350,000 stock options.
    • Total Undiluted Percentage: Approximately 13.13% of issued and outstanding common shares.
    • Total Partially Diluted Percentage: Approximately 13.91% of total issued and outstanding common shares.
  • Regulatory Filing: Early Warning Report filed with securities regulatory authorities in Canada pursuant to National Instrument 62-103.
  • Future Intent: The acquiror may acquire additional securities or dispose of securities on the open market, privately, or otherwise, depending on market conditions, reformulation of plans, other available investment business opportunities, and/or other relevant factors.
Read the original news release →

More from Optimi Health Corp

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory